While the active ingredient is the same molecule used in brand-name formulations, the manufacturing process, quality control, potency verification, and sterility assurance differ significantly
Key variables include adult obesity prevalence, new GLP-1 prescription starts, average selling price erosion, reimbursement penetration, pipeline success rates, and fill rate constraints
Per prior brand-published disclosures and established medical guidance: HRT carries documented risks including blood clots, stroke, breast cancer (risk varies by formulation, timing, and individual health history), and endometrial cancer (a retained FDA warning for systemic estrogen-alone products in women with a uterus)
The GLP1R gene variant (rs6923761) and GIPR variant (rs1800437) influence receptor sensitivity and signaling efficiency, meaning some individuals see faster appetite suppression while others require a slightly longer adjustment period